EP
SRPT icon

Essential Partners’s Sarepta Therapeutics SRPT Stock Holding History

Essential Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14K Sell
781
-5,003
-86% -$94.6K 0.01% 1058
2026
Q1 		$126K Sell
5,784
-2,642
-31% -$51.1K 0.04% 370
2025
Q4 		$181K Buy
8,426
+5,372
+176% +$113K 0.06% 333
2025
Q3 		$58.9K Buy
+3,054
New +$54.4K 0.02% 558

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Essential Partners's SRPT Position: Q2 2026 in Review

Essential Partners reduced its Sarepta Therapeutics (SRPT) stake by 86% in Q2 2026, selling an estimated $94.6K and leaving 781 shares worth $14K. The position accounts for 0.01% of the portfolio, ranked #1058.

Essential Partners first reported a position in SRPT in Q3 2025 and has held it in 4 quarters since. The position peaked at $181K in Q4 2025. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Essential Partners held 781 shares of Sarepta Therapeutics worth $14K as of Q2 2026.
  • Essential Partners sold 5,003 Sarepta Therapeutics shares in Q2 2026, an estimated $94.6K.
  • Sarepta Therapeutics made up 0.01% of Essential Partners's portfolio in Q2 2026, its #1058 holding.
  • Essential Partners first reported a position in Sarepta Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Essential Partners's Sarepta Therapeutics position peaked at $181K in Q4 2025.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.